concomit whole-abdomin radiat intraperiton chemotherapi advanc ovarian carcinoma pilot studi use cisplatin-bas chemotherapi ovarian carcinoma surviv rate whole-abdomin radiat war single-ag chemotherapi pilot studi feasibl concomit radiat chemotherapi eleven patient stage iii IV ovarian carcinoma cgi war intraperiton IP cisplatin addit IP cisplatin surgeri toxic moder sixty-four percent patient grade hematolog toxic hospit sepsi war/ip cisplatin hematolog toxic pronounc IP cisplatin patient moder gastrointestin toxic averag percentag total bodi fifty-f percent patient complet clinic respons patient minim postop residu diseas patient persist diseas acut nonlymphocyt leukemia anll month initi diagnosi patient residu diseas mm patient mm free diseas toxic addit combin war IP cisplatin therapeut efficaci compar standard chemotherapi regimen therapeut surviv advantag use treatment protocol 